Spyre Therapeutics (SYRE) news
Recent news
Agility Robotics and Churchill Capital Corp XI S-4 registration statement declared effective by SEC in connection with proposed business combination
The U.S. Securities and Exchange Commission (SEC) has declared effective the registration statement on Form S-4 filed by Agility Robotics, Inc. and Churchill Capital Corp XI (NASDAQ: CCXI) in connection with their proposed business combination . This development marks a key step toward the…
AInvest Wire · 2d agoAdani Green Generation capacity 20.8 GW at end-Sept, +24% y/y
Adani Green Energy Ltd (AGEL) has reported a significant increase in its renewable energy generation capacity, reaching 20.8 gigawatts (GW) as of the end of September 2026, representing a 24% year-over-year growth . This expansion underscores the company’s ongoing commitment to scaling India’s…
AInvest Wire · 5d agoSpyre Therapeutics shares slip 2.8% after co prices $350 million stock offering
Spyre Therapeutics, Inc. (Nasdaq: SYRE) announced the pricing of a $350 million public offering of 4,117,648 shares of its common stock at $85.00 per share, with the offering expected to close on or about October 7, 2026, subject to customary conditions . Following the announcement, the company’s…
AInvest Wire · Oct 6, 2026Spyre Therapeutics shares slip 1.7% premarket after co prices $350 million stock offering
Spyre Therapeutics Inc. (SPYR) shares declined 1.7% in premarket trading on October 6, 2026, following the company’s announcement of a $350 million stock offering. The offering, which includes the sale of newly issued shares, is intended to support ongoing research and development efforts across…
AInvest Wire · Oct 6, 2026Spyre Therapeutics prices $350M offering of stock
Spyre Therapeutics, Inc. (Nasdaq: SYRE) has priced a public offering of 6,500,000 shares of its common stock at $62.00 per share, generating gross proceeds of approximately $403.0 million before underwriting discounts and expenses. The offering, which is expected to close on or about April 16,…
AInvest Wire · Oct 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.